Call to Action for Participation in Clinical Trials is Topic of Symposium at Alzheimer's Disease International Conference 2016

HAMILTON, Bermuda, April 19, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON) today announced it is sponsoring a symposium at the Alzheimer's Disease International Conference 2016: "Alzheimer's Community Call to Action: Developing New Treatments Through Clinical Trial Participation." 

The session will include presentations by Marc Wortmann, executive director of Alzheimer's Disease International, and Professor Harald Hampel, AXA-UPMC Chair on Alzheimer's Disease at the Pierre and Marie Curie University, Paris. 

Dr. Hampel will discuss the reemergence of the cholinergic system as a promising target in late-stage Alzheimer's clinical research.  Mr. Wortmann will discuss what caregiving organizations can do to help educate their members about available clinical research opportunities and the importance of considering participation.

The symposium is set for 6:45 a.m. EDT/12:45 p.m. CEST on Saturday, April 23, at the Alzheimer's Disease International Conference 2016 in Budapest, Hungary.  It will be live-streamed online at www.AlzheimersGlobalResearch.com/ADIevent.  The livestream will remain online after the event is complete.

"No new chemical entity has been approved for treatment of Alzheimer's disease in over a decade, but there are several potential treatments in the final stages of clinical development," said Dr. Hampel.  "I look forward to sharing more information about the latest research trends, and the important role patients and caregivers play in contributing to this research."

"Too often, people with dementia and their caregivers may not be aware of clinical trial opportunities available to them, or the importance of participation," said Mr. Wortmann.  "I look forward to sharing information on what Alzheimer's associations can do to help educate their members about these opportunities."

About Dr. Hampel and Mr. Wortmann

Dr. Harald Hampel is a world authority on Alzheimer's disease and related neurodegenerative diseases. He is Professor and AXA Research Fund and UPMC Chair at the Sorbonne Universities, Pierre and Marie Curie University (UPMC) in Paris, France. He is Scientific Director of the Institute for Memory and Alzheimer's disease (IM2A) and affiliated to the Brain and Spine Institute (ICM), Department of Neurology, Pitié-Salpétrière University Hospital.

Dr. Hampel has published more than 600 peer-reviewed research papers, 80 book chapters and eight books, many in world-leading scientific journals. Dr. Hampel is Senior Associate Editor of the leading international Alzheimer's journal Alzheimer's & Dementia, the journal of the Alzheimer's Association.

Marc Wortmann has served as executive director of Alzheimer's Disease International (ADI) since November 2006. Prior to joining ADI he was the Executive Director of Alzheimer Nederland and has been a speaker at many international conferences on educational awareness, patient advocacy, public policy and ethical issues.

About Axovant
Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral components of dementia and related neurological disorders. Axovant's vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of the disease.

Logo - http://photos.prnewswire.com/prnh/20150629/226455LOGO

SOURCE Axovant Sciences Ltd.

Related Links

http://www.axovant.com